Moderna announced that its COVID-19 vaccine appears to provide protection against several new coronavirus strains, including the Delta variant that is spreading rapidly around the world. “These findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine,” CEO Stephane Bancel said in a press release.
Moderna also said that the government of India granted an Emergency Use Authorization for its COVID-19 vaccine in adults aged 18 years and older. “I want to thank the government of India for this authorization, which marks an important step forward in the global fight against the pandemic,” Bancel said. “We are committed to making our COVID-19 vaccine available around the world.”
Moderna’s vaccine has emerged as a vital weapon in the global battle against COVID-19. With the drug continuing to display a remarkable efficacy and safety profile, governments around the world are ramping up their purchases of the life-saving vaccine. Moderna’s stock, in turn, has delivered fortune-building returns to investors along the way, including a 124% surge so far in 2021. And with effective coronavirus protection as important today as ever, more gains appear likely.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Need Your Help Today. Your $1 can change life.